Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells, according to a new study published in Nanoscale. The study, conducted in partnership by researchers at Nemours Children’s Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.
“High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor. This research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient’s health,” said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children’s Health System and senior author of the study. “Unique approaches to target tumor cells with nanoparticle delivery systems hold promise for treatment of resistant tumors, such as the high risk neuroblastoma. We are hopeful that in the future, nanoparticles can be utilized to personalize care to patients and reduce the late effects of therapy.”
Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys. About 700 new cases of neuroblastoma are diagnosed each year in the United States and most cases appear in children younger than 5 years old. High-risk neuroblastoma is hard to cure and is more likely to become resistant to standard therapies or recur. These cancers are also associated with late effects after treatments have ended, including developmental delays, hearing loss, or other disabilities.
Curcumin has been shown to have substantial anti-cancer ability, but its low solubility and poor stability have made its use in medicinal applications challenging. Researchers from Nemours and UCF found that nanoparticles can be used to deliver curcumin to tumor sites.
“This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,” said Professor Sudipta Seal, who directs of UCF’s NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study. “More research is needed, but we are hopeful it could lead to more effective treatment of this devastating disease in the future.”
In the study, researchers loaded Cerium oxide nanoparticles with curcumin and coated them with dextran to test in cell lines of a high-risk form of neuroblastoma, known as MYCN-amplified, as well as non-amplified neuroblastoma. This formulation induced substantial cell death in neuroblastoma cells while producing no or only minor toxicity in healthy cells. Overall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.
Nanoscience research, which explores the unusual properties of materials at the nanoscale, has led to advancements in medicine, energy, information storage, computing and other fields. At no more than 100 nanometers, nanoparticles are exceedingly small. By comparison, a sheet of paper is about 75,000 nanometers thick.
This study was conducted in a laboratory setting in Orlando, at Nemours Children’s Hospital and the University of Central Florida in cells from children with neuroblastoma, but researchers hope to begin to use these curcumin nanoparticles with micro RNA in animal models to direct the molecule to a tumor site.
Learn more: UCF, Nemours Collaborate to Defeat Difficult-to-Treat Childhood Cancer
The Latest on: Neuroblastoma
[google_news title=”” keyword=”neuroblastoma” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Molecular Characterization and Classification of Neuroblastomaon May 24, 2023 at 5:00 pm
Gene-expression-based analyses reflect neuroblastoma tumor behavior and may accurately predict patient outcome. Global genomic pattern and gene-expression-based classifiers will replace current ...
- Y-mAbs’ Danyelza injection receives marketing approval in Brazilon May 24, 2023 at 3:18 am
Y-mAbs has received marketing authorisation for Danyelza (naxitamab-gqgk) 40mg/10mL injection from the Brazilian Health Regulatory Agency ...
- Ten Challenges in the Management of Neuroblastomaon May 23, 2023 at 5:00 pm
Neuroblastoma is a complex disease with many contradictions and challenges. It is, by and large, a cancer of babies and preschool children, but it does occur, albeit increasingly rarely ...
- Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazilon May 23, 2023 at 6:00 am
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic ...
- Nonprofit organization on a mission to help send 4-year-old battling cancer to Walt Disney Worldon May 22, 2023 at 8:56 am
Xander Keith was first diagnosed with Stage 4 neuroblastoma at 10 weeks old. Years after being in remission, the cancer has returned.
- Neuroblastomaon May 19, 2023 at 5:03 am
Neuroblastoma is a cancer that develops from immature nerve cells found in several areas of the body. Neuroblastoma most commonly arises in and around the adrenal glands, which have similar origins to ...
- CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trialon May 15, 2023 at 12:24 pm
NKT cells were modified to express a GD2-specific chimeric antigen receptor (GD2 CAR), which enables the immune cells to target a molecule found on the surface of neuroblastoma cells, and ...
- CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trialon May 15, 2023 at 9:33 am
In the new article, investigators describe the results obtained in 12 patients with stage 4 relapsed neuroblastoma that was resistant to other therapies. They found that the therapy was safe for ...
via Google News and Bing News